Aurinia Pharmaceuticals Inc. Aktie News

Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential increase in US sales and from international markets paired with cost savings could make Aurinia cash flow positive by the end of the year.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.

U.S.-listed shares of Aurinia Pharmaceuticals (AUPH.O) witnessed a significant downturn, plummeting 25% to $6 in pre-market trading. The pharmaceutical company announced the conclusion of its strategic review, initiated in June 2023, but failed to attract any formal offers, a report by Reuters said.

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript